As for the improvements, SIGNAL offers private and excess D&O coverage with limits up to $5 million, covering a wide range of ...

Synchron also reported evidence the device worked in the six-patient trial, with the conversion of brain signals to motor ...

Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease ...

Researchers assessed the safety, efficacy, and tolerability of various doses of zasocitinib among patients with moderate to severe plaque psoriasis.

For most people, a case of COVID-19 is easily treatable at this point in time. “Most” isn’t everyone, though, and the ...

The Pediatric Clinical Trials Office at Children’s of Alabama is helping lead the way in finding the best treatments for ...

William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data ...

ProJenX teamed with Unlearn to create digital twins of ALS patients as a placebo group in open-label extension of Phase 1 ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

The trial (NCT06053840) enrolled 100 adult patients who received chloral hydrate treatment over 14 days and came from primary and secondary care sites. Patients were closely monitored by a virtual ...